William Blair analyst Ryan Daniels has reiterated their bullish stance on WAY stock, giving a Buy rating on April 28.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Ryan Daniels has given his Buy rating due to a combination of factors that highlight Waystar Holding Corp.’s strong performance and future potential. The company reported better-than-expected first quarter 2025 results, with revenue exceeding consensus estimates by 3.4%, driven by positive new business momentum and solid utilization trends. Additionally, Waystar demonstrated strong operating leverage and effective expense management, resulting in an 8.4% beat on adjusted EBITDA.
Moreover, despite the uncertain macroeconomic environment, Waystar’s pipeline remains robust, indicating continued momentum for its platform. The company’s revenue cycle management services are seen as a critical investment priority for healthcare providers, and its largely recurring revenue stream provides strong visibility into future performance. Consequently, management has modestly increased its 2025 outlook across key metrics, reinforcing the company’s position as a high-quality growth opportunity with potential for sustained market share expansion.
In another report released on April 28, Barclays also maintained a Buy rating on the stock with a $45.00 price target.
Based on the recent corporate insider activity of 46 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of WAY in relation to earlier this year.